Gottlieb and Weisbrod Back Under One Roof

They were the masterminds behind two different healthcare companies and were separated for twenty years but, at long last, Jacob Gottlieb and Stuart and Weisbrod will finally be sharing a building once again. The two first co-founded a company known as Merlin Biomed Group in 1998 and, for almost a decade, it served as an investment management company dedicated to improving the healthcare sector and preventing people from going into debt because of unpaid medical bills.

Gottlieb served as the portfolio manager for the company and, despite their many years of success and prosperity, the company eventually ended up closing its doors back in 2007 at which point the two promptly parted ways. Gottlieb and Weisbrod would eventually go on to found separate companies as Weisbrod became the founder and CEO of Iguana Healthcare Partners whilst Gottlieb launched Visium Asset Management back in 2008. Of course, this was around the time of the stock market crash but, fortunately, Gottlieb managed to pull through and transform the company into an 8 billion dollar hedge fund with over 200 dedicated employees and offices in numerous major cities throughout the world such as NYC, San Francisco, and London.

Of course, all that success was eventually brought to an abrupt end after a whistleblower revealed there had been insider trading and mismarking occurring throughout the company for over two years now. Gottlieb himself was never actually charged with any crimes and the company never conceded to any malfeasance but, nevertheless, he did consent to pay out $10 million in reparations. Now that the two will be working together once more, it promises to be a fresh start for both businessmen as they seek to rebuild and begin a new project. It promises to offer some exciting prospects for the future of the healthcare industry.

A Look At Biotechnology Veteran Clay Siegall

Clay Siegall is the Chairman of the Board and CEO of Seattle Genetics, Inc. He enjoys spending some of his time linking to articles he finds of interest on his blog. A recent NPR article he linked to describes how a tiny fish has an opioid-like venom that enables it to escape predators. This fish, called the Fangblenny (due to its huge fangs in comparison to its body), can carve up larger fish in the blink of an eye. When it is eaten by another fish, it releases this venom which disorients the fish while the Fangblenny uses its fangs to bite its way out of the fishes mouth. For this reason, the Fangblenny is called the jerk of the sea.

Another interesting article that Dr. Siegall linked to is about a paralyzed man who, equipped with the latest technology, can control one of his arms and hands using his mind. Bill Kochevar, 56, was paralyzed in a biking accident in his 40’s. The device he uses to control his arm and hand, the BrainGate2, can detect signals in the area of the brain that controls those body parts after he had two electrode arrays surgically installed in his brain.

Due to Dr. Clay Siegall, Seattle Genetics is at the forefront of cancer drug research. He co-founded the company in 1997 in order to focus research on antibody-drug conjugates role in cancer drug therapies. He has also been the Director of Ultragenyx Pharmaceuticals, Inc. since 2014 and the Director of Alder Biopharmaceuticals, Inc since 2005. Another biotechnology company Dr. Clay Siegall is associated with is Mirna Theapeutics, Inc., where he has been on on its Board of Directors since 2013. He earned his BS from the University of Maryland and his Ph.D. from George Washington University.